Stockscreener 앱 받기
0.313
7.67%
-0.026
시간 외 거래:
.34
0.027
+8.63%
전일 마감가:
$0.339
열려 있는:
$0.3372
하루 거래량:
889.14K
Relative Volume:
0.15
시가총액:
$5.34M
수익:
$743.00K
순이익/손실:
$-7.63M
주가수익비율:
-0.1043
EPS:
-3
순현금흐름:
-
1주 성능:
-10.78%
1개월 성능:
-24.76%
6개월 성능:
-71.02%
1년 성능:
-79.54%
1일 변동 폭
$0.313
$0.3372
1주일 범위
$0.313
$0.3948
52주 변동 폭
$0.28
$2.33
캔 파이트 바이오파마 Stock (CANF) Company Profile
명칭
Can-Fite Biopharma Ltd ADR
전화
972 3 924 1114
주소
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
CANF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.313 | 5.79M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
캔 파이트 바이오파마 Stock (CANF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-10-19 | 재개 | ROTH Capital | Buy |
| 2016-08-29 | 재개 | Rodman & Renshaw | Buy |
| 2015-11-30 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-31 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 재확인 | ROTH Capital | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
모두보기
캔 파이트 바이오파마 주식(CANF)의 최신 뉴스
Can Can Fite Biopharma Ltd Sponsored ADR stock survive global slowdown2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock sustain breakout momentum2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock test all time highsMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Can Fite Biopharma Ltd Sponsored ADR stock positioned for secular growth2025 Key Lessons & Growth Focused Entry Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
An analyst sees good growth prospects for Can-Fite Biopharma Ltd ADR (CANF) - Setenews
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - Sahm
Will Can Fite Biopharma Ltd Sponsored ADR stock beat revenue estimatesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong analyst pickJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
Can Can Fite Biopharma Ltd Sponsored ADR stock expand revenue streams - newser.com
Take off with Santech Holdings Ltd. ADR (STEC): Get ready for trading - Setenews
How does Can-Fite Biopharma Ltd ADR (CANF) change from a tortoise to a hare? - Setenews
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson - Sahm
캔 파이트 바이오파마 (CANF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
0.91%
자본화:
|
볼륨(24시간):